[ad_1]
The Botanix Pharmaceuticals Limited Medical Dermatology Company (ASX: Bot, "Botanix" or the "Company") is pleased to provide an update on the progress of the main pipeline development products (BTX 1801 and BTX 1308) and issued a presentation "Matt Callahan, executive director of Botanix, said:" With two programs ready to enter phase 2, we are very excited about the significant potential of our pipeline products. The BTX 1801 has the potential to address the important global public health issue of antimicrobial resistance. In addition, the BTX1308 has the potential to provide a new topical solution for people with psoriasis that is safe and effective. "
The New Botanix Pipeline (BTX 1801) is a new antimicrobial agent that can address unmet needs in serious skin infections with market opportunities." Pre-clinical test data recently completed by the Company indicate that permetxTM significantly improves the antimicrobial killing power of cannabidiol, achieving nearly 100% bactericidal effect (at low concentrations) of antibiotic-resistant strains of the most common skin infection bacteria – Methicillin – Staphylococcus aureus resistant (known as MRSA) The development of new antimicrobials is currently the focus of a coordinated effort globally and commercial opportunities for new antimicrobials are important and many needs remain unsatisfied.
Botanix is now striving to complete, in collaboration with the prin Main opinion leaders, market review in order to identify the ideal skin infection to initially target for BTX 1801, with the intention of performing a fast development path. The presentation of the BTX 1801 describes the unmet market needs, the favorable market dynamics, the potential upward value, the preclinical data BTX 1801 and the BTX 1801 development pathway.
Botanix also completed its prepa- clinic and its psoriasis screening test. supports the mechanism of action of the drug in the treatment of inflammation, bacterial infection and modulation of the immune system. With this data in hand, Botanix is advancing a psoriasis study that will compare a number of BTX 1308 formulations to a placebo, a study scheduled to begin in Europe at the end of the 3rd quarter of the year. 2018. More details on the design of the study for BTX 1308 will be provided at a later date.
About Botanix Pharmaceuticals
Botanix Pharmaceuticals Limited (ASX: BOT) is a clinical stage medical dermatology company based in Perth, Australia and Philadelphia. . The goal of the Company is the development of safe and effective topical treatments for acne, psoriasis, atopic dermatitis and other skin conditions. The active ingredient contained in Botanix products is a synthetic form of a widely studied natural compound. Therapeutic targets include inflammation, deterioration of the skin barrier, proliferation of skin cells, pruritus (itching), excess sebum and bacterial infection.
Botanix holds an exclusive license to use an exclusive drug dispensing system. delivery of active pharmaceutical products in all skin diseases. Botanix works with several parties to test the PermérexTM application both on the basis of a paid license and a traditional license.
Botanix is pursuing a rapid clinical development strategy to accelerate the commercialization of products. The duration of treatment of patients in clinical studies is usually completed within 4 to 12 weeks.
The Company completed its first acne patient studies with BTX 1503 in January 2018 and began a phase 2 clinical trial in June 2018. mid-2019. The Phase 1b study on atopic dermatitis of BTX 1204 patient was completed in June 2018 and the preparation of a Phase 2 clinical trial is underway. Another Phase Ib BTX 1308 study on psoriasis is also expected to begin in the 3rd quarter of fiscal 2018.
Source link
